<DOC>
	<DOC>NCT00617747</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches</brief_summary>
	<brief_title>Efficacy and Tolerability of Zolmitriptan Nasal Spray</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Subject has an established diagnosis of migraine headache, with or without aura Subject has a medical history indicating the presence of migraine attacks for at least 1 year before the start of the trial or a minimum of 2 and maximum of 6 migraine attacks per month on average for 3 months preceding the study Subject has non migraine headaches on fewer than 6 days each month for 3 months preceding the study Subject has history of basilar, ophthalmoplegic or hemiplegic migraine or serious neurologic condition associated with headache Subject has used a MAOI within 2 weeks of randomisation or has been given SSRI therapy or migraine prophylactic agent within 3 months of randomisation. Subject requires treatment with propranolol or cimetidine or has had an intolerable or serious adverse event while using another triptan Subject has a history or symptoms suggestive of ischemic heart disease, coronary artery vasospasm or other significant underlying cardiovascular disease or clinically significant abnormalities seen on an ECG or uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Zolmitriptan</keyword>
	<keyword>ZOMIG</keyword>
	<keyword>migraine</keyword>
	<keyword>headache response</keyword>
	<keyword>headache</keyword>
	<keyword>headache pain</keyword>
</DOC>